A new clinical trial has found that tirzepatide, sold under the name Zepbound, led to significantly greater weight loss in people with obesity compared to semaglutide, known as Wegovy
Strategies to Maintain Weight Loss After Stopping GLP-1 Medications Successful weight maintenance after GLP-1 discontinuation requires a multi-faceted approach: establishing consistent meal timing, maintaining high protein intake (25-30% of calories), incorporating strength training at least 2x weekly, and tracking hunger patterns to identify early rebound signals
Tirzepatide: A dual GIP/GLP-1 receptor agonist administered once weekly
Addressing Tolerability or Side Effects Although both medications share similar gastrointestinal side effect profiles, individual responses can vary
Understanding these differences helps patients and clinicians select the most appropriate formulation based on treatment goals, lifestyle preferences, and individual medical needs